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Edimer Pharmaceuticals, a com-
pany developing EDI200, a protein
therapy, to treat the symptoms of
patients affected by X-linked hypo-
hidrotic ectodermal dysplasia (https://
nfed.patientcrossroads.org/).
(2) The Dystrophic Epidermolysis Bul-
losa Research Association (DEBRA)
launched EBCare, the first online
international patient-reported registry
for all forms of epidermolysis bullosa
(http://www.ebcare.org), with funding
from Lotus Tissue Repair, a company
developing recombinant collagen VII
for treatment of dystrophic epidermo-
lysis bullosa.
Multiple companies may jointly spon-
sor a shared registry for a specific dis-
ease, thereby sharing costs and reducing
both patient fragmentation and patient
survey fatigue, within a framework that
protects intellectual property.
Unlike academic registries that are
usually presented only in one language
and in a few countries, company-spon-
sored registries are usually international
registries that are translated into several
major languages. For example, the
NFED registry is currently available in
English, Spanish, German, French, and
Italian. Thus, well-funded, company-
sponsored, multilingual registries can
facilitate collection of data in a single
unified database.
To address the unmet needs shared
throughout the rare disease community,
the NIH ORDR has recently launched the
Global Rare Diseases Patient Registry and
Data Repository (http://grdr.info) program
(Rubinstein et al., 2010). Through a pilot
program, new registries will be deve-
loped using the PatientCrossroads web-
based patient registry program (http://
www.patientcrossroads.com), and an
infrastructure will be developed to create
a repository of patient natural history
and biorepository information. The GRDR
repository will enable analyses of data
across rare diseases and will facilitate
clinical trials and research studies, thereby
accelerating rare disease research.
Although there is no single solution to
securing sustained funding for patient
registries, it is disappointing that registries
that were maintained (with NIH support)
for a decade or more are being terminated.
We hope that academic institutions,
patient organizations, and companies
together can find solutions to keeping
these important resources in service.
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Engineering a New Mouse Model for
Vitiligo
Prashiela Manga1 and Seth J. Orlow1
Although the precise mechanisms that trigger vitiligo remain elusive, autoimmune
responses mediate its progression. The development of therapies has been impeded
by a paucity of animal models, since mice lack interfollicular melanocytes, the primary
targets in vitiligo. In this issue, Harris et al. describe a mouse model in which
interfollicular melanocytes are retained by Kit ligand overexpression and an
immune response is initiated by transplanting melanocyte-targeting CD8þ T cells.
Journal of Investigative Dermatology (2012) 132, 1752–1755. doi:10.1038/jid.2012.140
Vitiligo
Melanocytes synthesize melanin, the pig-
ment that provides color to skin, hair,
and eyes, while protecting against sun-
induced damage. Vitiligo causes a selec-
tive, progressive loss of melanocytes,
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which leaves white patches on the skin
and, in severe cases, hair devoid of
pigment. Vitiligo affects B1% of the
population in the United States, although
incidences as high as 8% have been
reported in other areas of the world.
Clinical presentation and treatment
Vitiligo affects both men and women
in all populations and can present at
any age, although disease onset typi-
cally occurs during the first two decades
of life. There are two major sub-
types of vitiligo, generalized and seg-
mental, defined by the distribution of
the lesions. The more common form
in adults is generalized vitiligo (viti-
ligo vulgaris), in which depigmented
macules and patches have a sym-
metrical distribution throughout the
body. In segmental vitiligo, which is
more common in children, depigmenta-
tion is unilateral and confined to one
body zone.
Common sites of initiation in vitiligo
vulgaris are around body orifices and
on hands, knees, and elbows. As the
disease progresses, lesions may increase
in size and additional lesions may arise
in distant areas. The highly visible nat-
ure of the disorder results in stigmatiza-
tion, particularly among darker-skinned
individuals. Affected persons and their
families may thus experience severe
psychosocial burdens. In one study,
66% of participants with vitiligo felt
embarrassed about their appearance,
and more than half felt uncomfortable
socializing, leading to severe depression
in some patients, and in rare instances
to suicide (Porter et al., 1987).
There is no cure for vitiligo. Although
several treatment options aimed at res-
toring pigmentation are available, their
efficacy varies considerably. Only about
50% of patients respond successfully to
treatments, with no clear indicators that
would suggest which strategy would
be most effective in a specific patient.
Treatments include topical cortico-
steroids or calcineurin inhibitors, as well
as the use of narrow-band UV B or UV
A radiation combined with the admin-
istration of oral photosensitizing com-
pound such as psoralen. Excimer laser
treatment and surgical replenishment of
melanocytes are useful in some patients.
In individuals with extensive disease,
total body chemical depigmentation,
with agents such as monobenzyl ether
of hydroquinone, is an alternative
approach.
The development of targeted thera-
pies has been hampered by the lack of
clarity with regard to the pathobiology
of vitiligo. It is, however, clear that
nonsurgical therapies are most effective
for patients in whom hairs in lesional
areas remain pigmented, suggesting that
melanocytes in hair follicle repopulate
the skin. In fact, treatment success is
often heralded by the development of
perifollicular repigmentation.
Vitiligo therapy
development may be
accelerated by the
availability of a
mouse model with
interfollicular
melanocytes.
Disease pathobiology
The etiology underlying vitiligo remains
to be elucidated. An accepted model
postulates that a trigger induces loca-
lized melanocyte death and instigates
an autoimmune response that then
causes melanocyte destruction in areas
distant from the site of initiation
(Figure 1).
Environmental and physiological factors
are the most common triggers. Onset has
been reported to occur following trauma,
vaccination, radiotherapy, and expo-
sure to cytotoxins and chemicals, such
as phenolic compounds with structural
similarity to the melanin precursor tyro-
sine, particularly 4-tertiary butylphenol
and monobenzyl ether of hydroquinone.
Sun exposure, stress, and pregnancy may
also contribute to disease onset. However,
in most cases, the trigger is not known. It
has been suggested that a common factor
is the stimulation of melanin synthesis
(Boissy and Manga, 2004). Alternatively,
these triggers may result in the generation
of reactive oxygen species that cause
melanocyte damage and death. Several
studies have reported increased indicators
of oxidative stress in perilesional tissues
and sera, and in melanocytes cultured
from individuals with vitiligo (Halder and
Chappell, 2009).
Several alternative theories have been
proposed for melanocyte loss, including
compromised stability due to defective
adhesion molecules, particularly when
lesions occur at sites of friction, and
targeting by neuropeptides following nerve
damage (Le Poole et al., 1993). Regardless
of the initiating factor, melanocyte death is
thought to be caused by either necrosis or
apoptosis and by the subsequent presen-
tation of melanocyte-specific antigens that
elicit an immune response.
There is also considerable evidence for
a genetic component to the disease; for
example, vitiligo frequently affects more
than one individual in a family. Vitiligo
appears to be a complex disease, inher-
ited in a non-Mendelian manner with
incomplete penetrance. The disease is
genetically heterogenous, and it has been
reported to be associated with sequence
variants at multiple loci (Spritz, 2011).
Autoimmunity is a key component in
vitiligo progression. A number of groups
have reported the presence of antibodies
targeted against melanocyte-specific pro-
teins (including PMEL17) in sera from
patients, whereas a number of patients
with vitiligo have other autoimmune dis-
orders including type 1 diabetes, hypo-
thyroidism, celiac disease, Addison’s
disease, psoriasis, and rheumatoid arthri-
tis (Halder and Chappell, 2009). Fifteen
of the 16 genes implicated in recent
genome-wide association studies are
involved in immune response pathways
and/or autoimmune disease, including
genes localized to the major histocom-
patibility complex loci on chromosome
6p21.3 (Spritz, 2011) (Figure 1). Only
one melanocyte-specific gene, tyrosi-
nase, has been shown to be associated
with vitiligo. The disease-related variant
(R402) results in a protein that can be
presented at the melanocyte surface
more readily by HLA class I molecules
than tyrosinase encoded by the minor
allele (402Q), which in fact associates
with reduced risk of vitiligo (Spritz,
2011). Interestingly, susceptibility genes
and disease-associated alleles appear to
vary in significance depending on
ancestry. It is likely that other mela-
nocyte-specific genes play roles, given
that autoantibodies have been identified
against multiple targets. For example, the
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R402 variant is rare in non-Caucasian
populations, where other antigens may
play more prominent roles.
Several studies have suggested a role
for cytokine imbalance in vitiligo, with
expression of cytokines shown to be
altered in lesional tissues. For example,
interleukins 2R, 6, and 8 have been
shown to be increased in lesional skin,
which may contribute to the immune
response. Furthermore, there is evidence
for increased expression of INF-g in
vitiligo (Moretti et al., 2002).
A key factor in the immune response
in vitiligo is melanocyte destruction,
which is mediated by CD8þ cytotoxic
T lymphocytes (CTLs). Increased levels
of CD4þ and CD8þ T cells have been
observed in perilesional areas, whereas
INF-g has been shown to enhance
recruitment of T cells to the skin by
promoting ICAM-1 expression. CTLs iso-
lated from vitiligo lesions have been
shown to target melanocytes (van den
Wijngaard et al., 2000).
Animal models of vitiligo
Although the mouse has long served as
an excellent model for investigating
genes involved in skin and hair pigmen-
tation, its lack of interfollicular melano-
cytes has hampered the use of this
species in developing an animal model
of vitiligo. Depigmentation of the hair,
achieved by targeting melanocyte-spe-
cific proteins using CTLs, may be used
as a surrogate for interfollicular lesions;
however, as effective treatment requires
recruitment of melanocytes from the
hair follicles to repopulate the
depigmented epidermis, these models
have limited application in developing
therapies for vitiligo. An alternative
model is the Smyth line of chickens,
which lose feather pigmentation postna-
tally owing to immune-mediated
destruction of melanocytes (Shi and
Erf, 2012).
In this issue, Harris et al. (2012) des-
cribe a new murine model for vitiligo,
in which melanocytes are retained in
interfollicular areas by overexpression
of a mutant form of Kit ligand (KITL,
also known as stem cell factor or SCF),
and immune-mediated melanocyte loss
is triggered through transplantation of
melanocyte-targeting CD8þ T cells.
CTLs targeted against melanocyte-
specific proteins are thought to be a
major immunological component in
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Figure 1. Progression to vitiligo. AD, Addison’s disease; CD, celiac disease; CRD, Crohn’s disease; HT, Hashimoto’s thyroiditis; IBD, inflammatory bowel
disease; IGD, Grave’s disease; MITF, microphthalmia transcription factor; MS, multiple sclerosis; PS, psoriasis; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus; SS, systemic sclerosis; T1D, type 1 diabetes.
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melanocyte destruction. Thus,
transplanting CTLs targeting PMEL (also
known as PMEL17, SILV, or gp100), a
melanocyte-specific protein, mimics the
disease. Selection of PMEL is relevant
given that PMEL-targeting autoanti-
bodies have been reported in serum
from individuals with vitiligo (Kemp
et al., 2001). As is common in vitiligo,
the resulting depigmentation in this
model is limited to the skin, whereas
the hairs remain pigmented. The
histology of the resulting lesions
resembles that of active lesions in
human vitiligo. The loss of melano-
cytes appears to be attributable to
targeting by the transplanted CTLs,
given that other immune cells such as
CD4þ and CD11þ are not present at
elevated levels in areas of depig-
mentation.
Interestingly, only certain areas under-
go depigmentation in this model, with
the ears, rear footpads, and tails (areas
that typically have increased melano-
cyte numbers in wild-type mice)
being targeted preferentially. This also
reflects what is seen in humans, in whom
melanocyte loss occurs in specific areas
of the body more frequently than in
others.
A key difference between human
and mouse skin is sustained postnatal
expression of soluble KITL by human
keratinocytes. In mice, following birth,
KITL expression is limited to the hair
follicle, resulting in the absence of inter-
follicular melanocytes (Longley and
Carter, 1999). To drive the presence of
melanocytes in mouse epidermis, Harris
et al. (this issue, 2012) used transgenic
mice that overexpress a mutant form of
KITL that cannot be proteolyzed into
its soluble form, and thus remains mem-
brane bound and active. Although the
use of KITL to increase the population of
interfollicular melanocytes enables the
creation of a useful model, it adds an
element of complication given that
the KITL protein promotes the activity
of the microphthalmia transcription
factor (MITF), which itself regulates the
expression of many key genes involved
in melanocyte survival. Thus, although
this newly described mouse model
may be useful to study therapies that
target immune responses, utility in test-
ing repigmentation strategies may be
compromised by the presence of pro-
survival signals promoted by KITL and
MITF. One such treatment (afamela-
notide/Scenesse), a long-acting deri-
vate of alpha-melanocyte stimulating
hormone (which also promotes MITF
activity), is in clinical development,
in combination with UVR therapy
(Clinuvel Pharmaceuticals).
To demonstrate the utility of the
model, the authors investigated the
expression of INF-g, which is elevated
in human vitiligo lesions. Similar increa-
ses were observed in the mice, and
blocking IFN-g with antibodies reduced
both CD8þ T-cell accumulation in the
skin and depigmentation, even after
lesions had appeared. An added feature
that facilitates the ability to monitor
transplanted T cells is that they were
labeled with green fluorescent protein
under regulation of a promoter, which
results in expression in both CD4þ and
CD8þ cells. Thus, targeting IFN-g,
although complicated by potential side
effects, may be a useful approach in the
development of therapies for vitiligo, as
they may effectively quell the autoim-
mune response. Furthermore, INF-g-pro-
ducing CD8þ T cells have also been
implicated in segmental vitiligo; thus,
the mouse model may have broader
relevance in developing therapies
against this other form of vitiligo (van
Geel et al., 2012).
Although the new model by its nature
does not shed light on the factors that
lead to the onset of vitiligo and activa-
tion of the immune response, the model
described by Harris et al. (this issue,
2012) does recapitulate the autoimmune
destruction of epidermal melanocytes,
making it especially useful in the deve-
lopment of immunomodulatory thera-
pies for this common and disfiguring
condition.
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